Pages that link to "Q37278239"
Jump to navigation
Jump to search
The following pages link to Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial (Q37278239):
Displaying 50 items.
- The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review (Q24563917) (← links)
- Options for empagliflozin in combination therapy in type 2 diabetes mellitus (Q26745771) (← links)
- Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes (Q26749281) (← links)
- Empagliflozin (Q26773311) (← links)
- Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes (Q26864336) (← links)
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial (Q27301948) (← links)
- Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects (Q28072765) (← links)
- Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure (Q28080114) (← links)
- Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis (Q28553482) (← links)
- Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials (Q30248634) (← links)
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus (Q30249371) (← links)
- Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials (Q31105792) (← links)
- Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials (Q31112303) (← links)
- Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis (Q32186373) (← links)
- Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) (Q33812170) (← links)
- Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes (Q33837017) (← links)
- Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet (Q33857698) (← links)
- Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis (Q33885732) (← links)
- Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. (Q33890770) (← links)
- Update on developments with SGLT2 inhibitors in the management of type 2 diabetes (Q34198692) (← links)
- Empagliflozin in the treatment of type 2 diabetes: evidence to date (Q34502358) (← links)
- Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes (Q34699217) (← links)
- Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents (Q34973750) (← links)
- Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study (Q35117192) (← links)
- Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis (Q35157497) (← links)
- The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials (Q35260544) (← links)
- Short commentary on empagliflozin and its potential clinical impact (Q35528797) (← links)
- The role of empagliflozin in the management of type 2 diabetes by patient profile (Q35592873) (← links)
- Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes (Q35780861) (← links)
- Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview. (Q35831426) (← links)
- Novel Agents for the Treatment of Type 2 Diabetes (Q35910421) (← links)
- Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus (Q36257565) (← links)
- Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus (Q36345951) (← links)
- Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial (Q36402095) (← links)
- Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1) (Q36555418) (← links)
- The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus (Q36592820) (← links)
- Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus (Q36622125) (← links)
- Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride (Q36823710) (← links)
- A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes (Q36960633) (← links)
- The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis (Q37030680) (← links)
- Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial (Q37279276) (← links)
- Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option (Q37308941) (← links)
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes (Q37325818) (← links)
- Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control (Q37351709) (← links)
- Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus (Q37468412) (← links)
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus (Q37559421) (← links)
- Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement (Q37588847) (← links)
- Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor (Q37589626) (← links)
- Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis (Q37639297) (← links)
- Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure (Q38196340) (← links)